Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy
Maria Vittoria Dieci(Istituto Oncologico Veneto), Valentina Guarneri(Istituto Oncologico Veneto), Grazia Maria Vernaci(University of Padua), Giulia Tasca(University of Padua), Vassilena Tsvetkova(University of Padua), PierFranco Conte(University of Padua), Alberto Marchet(Istituto Oncologico Veneto), Silvia Michieletto(Istituto Oncologico Veneto), Michele Bottosso(University of Padua), Marcello Mele(University of Pisa), Carlo Alberto Giorgi(Istituto Oncologico Veneto), Gaia Griguolo(University of North Carolina at Chapel Hill), Elisa Genovesi(University of Padua), Silvia Angelini(Istituto Oncologico Veneto), Enrico Cumerlato(University of Padua)
Cited by 100
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|1k
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
|New England Journal of Medicine|2020|879
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830